Biogen
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Biogen sits in the top decile of US sponsors by registered trial count (#109 of 15,742 sponsors by registered trial count).
Biogen: 334 sponsored US clinical trials, 21 recruiting.
Biogen sponsors 334 registered US clinical trials on ClinicalTrials.gov, 21 of them currently recruiting, and 237 completed. 84 of these trials are in Phase 3-4 (later-stage) and 198 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Sclerosis, with 13 trials.
Top-decile sponsor footprint
Biogen ranks in the top decile of sponsors by registered trial count (#109 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
237 of 302 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
334 total, page 6 of 7
BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects
NCT01052506
BIIB014 Cardiovascular Monitoring Study
NCT01035515
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
NCT01004081
Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors
NCT01017198
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
NCT00970580
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
NCT00956436
Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure
NCT00955396
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
NCT00906399
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
NCT00811889
BG9928 in Subjects With Hepatic Impairment
NCT00858156
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
NCT00835770
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
NCT00745316
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
NCT00828204
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
NCT00746941
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
NCT00744679
BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis
NCT00771329
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
NCT00784836
Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
NCT00675428
Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
NCT00651443
Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency
NCT00709865
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
NCT00707512
Administration of BIIB028 to Subjects With Solid Tumors
NCT00725933
A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors
NCT00674947
A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis
NCT00616434
Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy
NCT00664027
A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers
NCT02125578
ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
NCT00618267
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)
NCT00618319
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors
NCT00618735
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT00801060
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
NCT00536120
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
NCT00555724
CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study
NCT00412412
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
NCT00538343
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
NCT00559702
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
NCT00529113
Evaluation of Natalizumab for thE Relief of MS Associated FatiGue
NCT00464074
BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)
NCT00523328
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
NCT00451451
Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction
NCT00550849
Avonex 15 Year Long Term Follow-up Study
NCT00525343
BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis
NCT00458861
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
NCT00420212
Pregnancy Exposure Registry for Tysabri®
NCT00472992
TYSABRI Global Observational Program in Safety
NCT00477113
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
NCT00424788
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT00391066
A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis
NCT00527410
Natalizumab High Titer Immunogenicity and Safety
NCT00516893
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
NCT00298272
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 135 |
| Phase 2 | 63 |
| Phase 3 | 71 |
| Phase 4 | 13 |
What is open in the Biogen pipeline
21 recruiting of 334 indexed (6% open); 237 completed (71%).
Phase mix: 84 late (III/IV) vs 198 early (I/II) (early-phase heavy).
Top condition: Multiple Sclerosis (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Biogen: open-pipeline peers nationwide
Peers matched on 334 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Biogen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 334 trials (± recruiting share)
- National Institute on Drug Abuse (NIDA) · 335 trials · 4% recruiting
- Genentech · 332 trials · 7% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Albert Einstein Healthcare Network · 6% recruiting · 48 trials
- Altimmune · 6% recruiting · 16 trials
- Bassett Healthcare · 6% recruiting · 16 trials
- Dynavax Technologies Corporation · 6% recruiting · 16 trials
Related
What to do with this Biogen page
334 registered trials is a research-attention snapshot, not an endorsement of Biogen or any single study.
- 21 of Biogen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Sclerosis is the condition Biogen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Biogen pipeline card: 334 registered trials from official public datasets.Report a data error.